

Cristina R Ferrone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5408446/publications.pdf>

Version: 2024-02-01

197
papers

12,620
citations

44069

48
h-index

27406

106
g-index

201
all docs

201
docs citations

201
times ranked

18480
citing authors

#	ARTICLE	IF	CITATIONS
1	Implications of Perineural Invasion on Disease Recurrence and Survival After Pancreatectomy for Pancreatic Head Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2022, 276, 378-385.	4.2	50
2	Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2022, 276, e502-e509.	4.2	6
3	Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy. <i>European Radiology</i> , 2022, 32, 2470-2480.	4.5	9
4	Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. <i>Surgery</i> , 2022, 171, 1379-1387.	1.9	7
5	Mutant IDH Inhibits IFN γ -TET2 Signaling to Promote Immune Evasion and Tumor Maintenance in Cholangiocarcinoma. <i>Cancer Discovery</i> , 2022, 12, 812-835.	9.4	55
6	Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2022, 276, e518-e526.	4.2	11
7	Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2022, 8, 462.	7.1	22
8	Differential role of HLA-A and HLA-B, C expression levels as prognostic markers in colon and rectal cancer. , 2022, 10, e004115.		9
9	EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion $^{+}$ Positive Cholangiocarcinoma. <i>Cancer Discovery</i> , 2022, 12, 1378-1395.	9.4	33
10	Tuberous sclerosis complex-associated nonfunctional pancreatic neuroendocrine tumors: Management and surgical outcomes. <i>American Journal of Medical Genetics, Part A</i> , 2022, 188, 2666-2671.	1.2	6
11	Abstract SY12-04: Multicellular spatial community featuring a novel neuronal-like malignant phenotype is enriched in pancreatic cancer after neoadjuvant chemotherapy and radiotherapy. <i>Cancer Research</i> , 2022, 82, SY12-04-SY12-04.	0.9	0
12	Spatial transcriptomics characterization of hepatocellular carcinoma using Molecular Cartography.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16110-e16110.	1.6	1
13	Revision of Pancreatic Neck Margins Based on Intraoperative Frozen Section Analysis Is Associated With Improved Survival in Patients Undergoing Pancreatectomy for Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2021, 274, e134-e142.	4.2	28
14	Simulated Volume-Based Regionalization of Complex Procedures. <i>Annals of Surgery</i> , 2021, 274, 312-318.	4.2	15
15	Intraductal Papillary Mucinous Neoplasms: Have IAP Consensus Guidelines Changed our Approach?. <i>Annals of Surgery</i> , 2021, 274, e980-e987.	4.2	22
16	Hepatectomy for Solitary Hepatocellular Carcinoma: Resection Margin Width Does Not Predict Survival. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1727-1735.	1.7	9
17	A Rare Case of Gallbladder Small Cell Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 561-564.	1.7	0
18	Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 182-191.	6.3	49

#	ARTICLE	IF	CITATIONS
19	Preoperative cholangitis is an independent risk factor for mortality in patients after pancreatoduodenectomy for pancreatic cancer. American Journal of Surgery, 2021, 221, 134-140.	1.8	17
20	B7-H3: An Attractive Target for Antibody-based Immunotherapy. Clinical Cancer Research, 2021, 27, 1227-1235.	7.0	162
21	Size of the Largest Colorectal Liver Metastasis Is an Independent Prognostic Factor in the Neoadjuvant Setting. Journal of Surgical Research, 2021, 259, 253-260.	1.6	4
22	A multi-institutional study of patient-derived gender-based discrimination experienced by resident physicians. American Journal of Surgery, 2021, 221, 309-314.	1.8	6
23	Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors. Journal of the American College of Surgeons, 2021, 232, 361-371.	0.5	23
24	Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. Journal of Gastrointestinal Surgery, 2021, 25, 2859-2870.	1.7	8
25	Prognostic impact of chemoradiation-related lymphopenia in patients with locally advanced pancreatic cancer.. Journal of Clinical Oncology, 2021, 39, 439-439.	1.6	0
26	Patient and Caregiver Considerations and Priorities When Selecting Hospitals for Complex Cancer Care. Annals of Surgical Oncology, 2021, 28, 4183-4192.	1.5	11
27	Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study. Molecular Imaging and Biology, 2021, 23, 456-466.	2.6	22
28	The use of elevated circulating hepatocyte growth factor (HGF) level as a potential prognostic biomarker in locally advanced pancreatic cancer.. Journal of Clinical Oncology, 2021, 39, 429-429.	1.6	2
29	Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation. Annals of Surgical Oncology, 2021, 28, 4592-4601.	1.5	9
30	Assessment of the Long-Term Impact of Pancreatoduodenectomy on Health-Related Quality of Life Using the EORTC QLQ-PAN26 Module. Annals of Surgical Oncology, 2021, 28, 4216-4224.	1.5	11
31	ASO Author Reflections: Long-Term Impact of Pancreatoduodenectomy on Pancreas-Specific Quality of Life. Annals of Surgical Oncology, 2021, 28, 4225-4226.	1.5	1
32	Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clinical Cancer Research, 2021, 27, 5586-5594.	7.0	178
33	Local and systemic recurrence following total neoadjuvant therapy (TNT) and resection for borderline resectable and locally advanced pancreatic adenocarcinoma: Long-term follow up from two phase II studies.. Journal of Clinical Oncology, 2021, 39, 4133-4133.	1.6	0
34	Divestment/skeletonization of the arteries in patients with advanced pancreatic ductal cancer. Surgery, 2021, 169, 1037-1038.	1.9	3
35	Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes.. Journal of Clinical Oncology, 2021, 39, e16253-e16253.	1.6	0
36	Analysis of in court malpractice litigation following pancreatic surgery. Pancreatology, 2021, 21, 819-823.	1.1	2

#	ARTICLE	IF	CITATIONS
37	Clinical impact of PET/MRI in oligometastatic colorectal cancer. British Journal of Cancer, 2021, 125, 975-982.	6.4	17
38	Promoting Women in Academic Medicine during COVID-19 and Beyond. Journal of General Internal Medicine, 2021, 36, 3292-3294.	2.6	3
39	Abstract 94: Multi-compartment reprogramming and spatially-resolved interactions in frozen pancreatic cancer with and without neoadjuvant chemotherapy and radiotherapy at single-cell resolution. , 2021, , .		0
40	Fibrohistiocytic Variant of Hepatic Pseudotumor. American Journal of Surgical Pathology, 2021, 45, 1314-1323.	3.7	6
41	The Impact of Neoadjuvant Treatment on Survival in Patients Undergoing Pancreatoduodenectomy With Concomitant Portomesenteric Venous Resection: An International Multicenter Analysis. Annals of Surgery, 2021, 274, 721-728.	4.2	24
42	Which Patient Do I Attend to First? Night-float Simulation to Assess Surgical Intern's Clinical Prioritization Skills. Journal of Surgical Education, 2021, 78, e226-e231.	2.5	0
43	CT and MRI features differentiating mucinous cystic neoplasms of the liver from pathologically simple cysts. Clinical Imaging, 2021, 76, 46-52.	1.5	9
44	Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. Pancreatology, 2021, 21, 1119-1126.	1.1	13
45	Open hepatic resection in the elderly at two tertiary referral centers. American Journal of Surgery, 2021, 222, 594-598.	1.8	1
46	Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 439-457.	4.9	564
47	Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2021, 39, 3773-3777.	1.6	17
48	Cholangiolar pattern and albumin in situ hybridisation enable a diagnosis of intrahepatic cholangiocarcinoma. Journal of Clinical Pathology, 2020, 73, 23-29.	2.0	14
49	Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1871-1884.	6.4	32
50	Effects of laparoscopic vs open abdominal surgery on costs and hospital readmission rate and its effect modification by surgeons' case volume. Surgical Endoscopy and Other Interventional Techniques, 2020, 34, 1-12.	2.4	7
51	Palliative External Beam Radiation Therapy for Hepatocellular Carcinoma With Right Atrial Tumor Thrombus. Practical Radiation Oncology, 2020, 10, e183-e187.	2.1	2
52	Main Pancreatic Duct to Parenchymal Thickness Ratio at Preoperative Imaging is Associated with Overall Survival in Upfront Resected Pancreatic Cancer. Annals of Surgical Oncology, 2020, 27, 1606-1612.	1.5	6
53	Does preoperative pharmacologic prophylaxis reduce the rate of venous thromboembolism in pancreatectomy patients?. Hpb, 2020, 22, 1020-1024.	0.3	9
54	Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes. Annals of Surgical Oncology, 2020, 27, 1400-1406.	1.5	22

#	ARTICLE	IF	CITATIONS
55	Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 1122-1129.	1.5	29
56	Reappraising the Concept of Conditional Survival After Pancreatectomy for Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2020, 271, 1148-1155.	4.2	19
57	Defining Benchmark Outcomes for Pancreatoduodenectomy With Portomesenteric Venous Resection. <i>Annals of Surgery</i> , 2020, 272, 731-737.	4.2	49
58	Reply to G.W. Peters et al and S. Shi et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 2947-2948.	1.6	0
59	Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 567289.	2.8	8
60	Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. <i>Annals of Surgical Oncology</i> , 2020, 27, 5161-5172.	1.5	4
61	Diagnosis of Depression is Associated with Readmission Following Elective Pancreatectomy. <i>Annals of Surgical Oncology</i> , 2020, 27, 4544-4550.	1.5	2
62	Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred?. <i>Journal of Clinical Oncology</i> , 2020, 38, 1757-1759.	1.6	19
63	Platelet and neutrophil to lymphocyte ratios predict survival in patients with resectable colorectal liver metastases. <i>American Journal of Surgery</i> , 2020, 220, 1579-1585.	1.8	12
64	Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI. <i>Clinical Cancer Research</i> , 2020, 26, 5007-5018.	7.0	29
65	A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma. <i>Journal of Translational Medicine</i> , 2020, 18, 255.	4.4	8
66	Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation. <i>Histopathology</i> , 2020, 77, 35-45.	2.9	9
67	Socioeconomic determinants of the surgical treatment of colorectal liver metastases. <i>American Journal of Surgery</i> , 2020, 220, 952-957.	1.8	9
68	Microscopic size measurements in post-neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes. <i>Histopathology</i> , 2020, 77, 144-155.	2.9	4
69	Variation in long-term oncologic outcomes by type of cancer center accreditation: An analysis of a SEER-Medicare population with pancreatic cancer. <i>American Journal of Surgery</i> , 2020, 220, 29-34.	1.8	19
70	Clinical staging in pancreatic adenocarcinoma underestimates extent of disease. <i>Pancreatology</i> , 2020, 20, 691-697.	1.1	9
71	Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 3898-3912.	1.5	13
72	Randomized trial of a perioperative geriatric intervention for older adults with cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 12012-12012.	1.6	28

#	ARTICLE	IF	CITATIONS
73	Patient-reported outcomes (PROs) in older adults with gastrointestinal (GI) cancer undergoing surgery.. Journal of Clinical Oncology, 2020, 38, e24032-e24032.	1.6	0
74	Failure to Refer Patients with Colorectal Liver Metastases to a Multidisciplinary Oncology Team Should be a “Never-Event” Journal of the National Medical Association, 2020, 112, 553-555.	0.8	2
75	Patient-reported outcomes (PROs) in older adults with gastrointestinal (GI) cancer undergoing surgery.. Journal of Clinical Oncology, 2020, 38, 159-159.	1.6	0
76	Clinical impact of PET/MR in treated colorectal cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2260-2269.	6.4	28
77	Facility Type is Associated with Margin Status and Overall Survival of Patients with Resected Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2019, 26, 4091-4099.	1.5	31
78	Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesions. Gastroenterology, 2019, 157, 720-730.e2.	1.3	44
79	Status of 5-Year Survivors of the Whipple Procedure for Pancreatic Adenocarcinoma. Advances in Surgery, 2019, 53, 253-269.	1.3	4
80	Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift. Frontiers in Oncology, 2019, 9, 1085.	2.8	48
81	Quasimesenchymal phenotype predicts systemic metastasis in pancreatic ductal adenocarcinoma. Modern Pathology, 2019, 32, 844-854.	5.5	4
82	Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs). Clinical Cancer Research, 2019, 25, 2644-2655.	7.0	56
83	Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer. JAMA Oncology, 2019, 5, 1020.	7.1	353
84	Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer. Cell, 2019, 178, 160-175.e27.	28.9	367
85	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion“Positive Intrahepatic Cholangiocarcinoma. Cancer Discovery, 2019, 9, 1064-1079.	9.4	254
86	Predictors of adjuvant treatment and survival in patients with intrahepatic cholangiocarcinoma who undergo resection. American Journal of Surgery, 2019, 218, 959-966.	1.8	14
87	Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. International Journal of Radiation Oncology Biology Physics, 2019, 105, 64-72.	0.8	99
88	Inoperable Biliary Tract and Primary Liver Tumors. Surgical Oncology Clinics of North America, 2019, 28, 745-762.	1.5	2
89	Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26835-26845.	7.1	69
90	Benchmarks in Pancreatic Surgery. Annals of Surgery, 2019, 270, 211-218.	4.2	202

#	ARTICLE	IF	CITATIONS
91	Hepatocellular Carcinoma in Transplantable Child-Pugh A Cirrhotics: Should Cost Affect Resection vs Transplantation?. Journal of Gastrointestinal Surgery, 2019, 23, 1135-1142.	1.7	6
92	Lower phosphate levels following pancreatectomy is associated with postoperative pancreatic fistula formation. Hpb, 2019, 21, 834-840.	0.3	5
93	Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. Oncologist, 2019, 24, 945-954.	3.7	13
94	Surgical resection versus ablation for early-stage hepatocellular carcinoma: A retrospective cohort analysis. American Journal of Surgery, 2019, 218, 157-163.	1.8	13
95	Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Annals of Surgery, 2019, 269, 733-740.	4.2	235
96	Number of Examined Lymph Nodes and Nodal Status Assessment in Distal Pancreatectomy for Body/Tail Ductal Adenocarcinoma. Annals of Surgery, 2019, 270, 1138-1146.	4.2	50
97	Hypofractionated radiation therapy for unresectable/locally recurrent intrahepatic cholangiocarcinoma.. Journal of Clinical Oncology, 2019, 37, 412-412.	1.6	1
98	Outcomes following liver SBRT for metastatic pancreatic cancer.. Journal of Clinical Oncology, 2019, 37, 418-418.	1.6	2
99	Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 202-210.	4.9	281
100	Dose intensity of neoadjuvant FOLFIRINOX (FFX) in borderline and locally advanced pancreatic cancer (LAPC): A comparison to the adjuvant benchmark.. Journal of Clinical Oncology, 2019, 37, 392-392.	1.6	2
101	Defective HLA class I antigen processing machinery in cancer. Cancer Immunology, Immunotherapy, 2018, 67, 999-1009.	4.2	68
102	Staging Laparoscopy Not Only Saves Patients an Incision, But May Also Help Them Live Longer. Annals of Surgical Oncology, 2018, 25, 1009-1016.	1.5	37
103	Hospital readmission after distal pancreatectomy is predicted by specific intra- and post-operative factors. American Journal of Surgery, 2018, 216, 511-517.	1.8	5
104	212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. Nuclear Medicine and Biology, 2018, 58, 67-73.	0.6	40
105	Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma. JAMA Oncology, 2018, 4, 963.	7.1	426
106	Neoadjuvant Chemotherapy in Pancreatic Cancer. , 2018, , 1187-1202.		1
107	Pancreatic neuroendocrine tumor: Correlations between MRI features, tumor biology, and clinical outcome after surgery. Journal of Magnetic Resonance Imaging, 2018, 47, 425-432.	3.4	26
108	Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas. Annals of Surgery, 2018, 267, 157-163.	4.2	105

#	ARTICLE	IF	CITATIONS
109	Effects of Intraoperative Fluid Management on Postoperative Outcomes. <i>Annals of Surgery</i> , 2018, 267, 1084-1092.	4.2	165
110	Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 656-661.	1.3	13
111	Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Annals of Surgery</i> , 2018, 268, 340-347.	4.2	39
112	ASO Author Reflections: Staging Laparoscopy Improves Overall Survival of Patients with Pancreatic Adenocarcinoma Found to Have Occult Metastatic Disease. <i>Annals of Surgical Oncology</i> , 2018, 25, 830-831.	1.5	0
113	Are Staging Computed Tomography (CT) Scans of the Chest Necessary in Pancreatic Adenocarcinoma?. <i>Annals of Surgical Oncology</i> , 2018, 25, 3936-3942.	1.5	10
114	Intraoperative Dexamethasone Decreases Infectious Complications After Pancreaticoduodenectomy and is Associated with Long-Term Survival in Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 4020-4026.	1.5	38
115	Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 4027-4034.	1.5	21
116	Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. <i>Practical Radiation Oncology</i> , 2018, 8, 414-421.	2.1	17
117	Association Between Changes in Body Composition and Neoadjuvant Treatment for Pancreatic Cancer. <i>JAMA Surgery</i> , 2018, 153, 809.	4.3	103
118	Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 166-181.	1.7	10
119	Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	2.4	60
120	Potentially curative combination of TGF- β 1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4116-4116.	1.6	9
121	Using circulating tumor DNA (ctDNA) to predict surgical outcome after neoadjuvant chemoradiation for locally advanced pancreatic cancer (LAPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 272-272.	1.6	7
122	Hepatocellular carcinoma surgical therapy: perspectives on the current limits to resection. <i>Chinese Clinical Oncology</i> , 2018, 7, 48-48.	1.2	19
123	Acinar cell cystadenoma: A challenging cytology diagnosis, facilitated by moray [®] microforceps biopsy. <i>Diagnostic Cytopathology</i> , 2017, 45, 557-560.	1.0	24
124	Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	82
125	Potential impact of a volume pledge on spatial access: A population-level analysis of patients undergoing pancreatectomy. <i>Surgery</i> , 2017, 162, 203-210.	1.9	40
126	Microscopic lymphovascular invasion is an independent predictor of survival in resected pancreatic ductal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2017, 116, 658-664.	1.7	32

#	ARTICLE	IF	CITATIONS
127	After Neoadjuvant Therapy, Imaging No Longer Provides a Clear Answer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 300.	0.8	2
128	Diabetes mellitus in intraductal papillary mucinous neoplasm of the pancreas is associated with high-grade dysplasia and invasive carcinoma. Pancreatology, 2017, 17, 920-926.	1.1	37
129	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science, 2017, 357, 1156-1160.	12.6	1,059
130	A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. Cancer Letters, 2017, 409, 9-19.	7.2	48
131	Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center. Gastroenterology, 2017, 153, 1284-1294.e1.	1.3	189
132	Primary lymph node gastrinoma: A single institution experience. Surgery, 2017, 162, 1088-1094.	1.9	12
133	Hepatocellular Carcinoma with Macrovascular Invasion: Defining the Optimal Treatment Strategy. Liver Cancer, 2017, 6, 360-374.	7.7	66
134	Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases. Journal of Gastrointestinal Surgery, 2017, 21, 1831-1840.	1.7	14
135	Reappraisal of Staging Laparoscopy for Patients with Pancreatic Adenocarcinoma: A Contemporary Analysis of 1001 Patients. Annals of Surgical Oncology, 2017, 24, 3203-3211.	1.5	37
136	Diverse repetitive element RNA expression defines epigenetic and immunologic features of colon cancer. JCI Insight, 2017, 2, e91078.	5.0	23
137	FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer (BRPC): Toxicity, R0 resection, and interim survival data from a prospective phase II study.. Journal of Clinical Oncology, 2017, 35, 4113-4113.	1.6	1
138	Phase II study of autophagy inhibition with hydroxychloroquine (HCQ) and preoperative (preop) short course chemoradiation (SCRT) followed by early surgery for resectable ductal adenocarcinoma of the head of pancreas (PDAC).. Journal of Clinical Oncology, 2017, 35, 4118-4118.	1.6	5
139	FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer: Preliminary toxicity and R0 resection rates from a prospective phase II study.. Journal of Clinical Oncology, 2017, 35, 368-368.	1.6	1
140	TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): Preliminary feasibility and R0 resection rates from a prospective phase II study.. Journal of Clinical Oncology, 2017, 35, 386-386.	1.6	13
141	Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. Oncotarget, 2017, 8, 37646-37656.	1.8	23
142	Neoadjuvant FOLFIRINOX for patients with borderline resectable or locally advanced pancreatic cancer: Results of a decision analysis.. Journal of Clinical Oncology, 2017, 35, 4117-4117.	1.6	0
143	Preoperative biliary drainage does not increase major complications in pancreaticoduodenectomy: a large single center experience from the <scp>Massachusetts</scp> General Hospital. Journal of Hepato-Biliary-Pancreatic Sciences, 2016, 23, 181-187.	2.6	53
144	Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors. Annals of Surgical Oncology, 2016, 23, 609-617.	1.5	24

#	ARTICLE	IF	CITATIONS
145	Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2016, 6, 727-739.	9.4	126
146	â€œIdealizedâ€•vs. â€œTrueâ€•learning curves: the case of laparoscopic liver resection. <i>Hpb</i> , 2016, 18, 504-509.	0.3	26
147	A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. <i>Biomaterials</i> , 2016, 93, 71-82.	11.4	35
148	Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 953-959.	1.7	12
149	Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma. <i>Advances in Surgery</i> , 2016, 50, 115-128.	1.3	6
150	Operative advancement is a never-ending obligation. <i>Surgery</i> , 2016, 160, 652-653.	1.9	1
151	Late Pancreatic Fistula After Pancreaticoduodenectomy: A Case Report and Review of the Literature. <i>Case Reports in Pancreatic Cancer</i> , 2016, 2, 65-70.	0.1	4
152	Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. <i>Cancer Discovery</i> , 2016, 6, 852-869.	9.4	318
153	The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology. <i>Annals of Surgical Oncology</i> , 2016, 23, 290-296.	1.5	80
154	Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 460-468.	1.6	363
155	Spectrum and Classification of Cystic Neoplasms of the Pancreas. <i>Surgical Oncology Clinics of North America</i> , 2016, 25, 339-350.	1.5	12
156	Discordance Between Perioperative Antibiotic Prophylaxis and Wound Infection Cultures in Patients Undergoing Pancreaticoduodenectomy. <i>JAMA Surgery</i> , 2016, 151, 432.	4.3	95
157	Operative Versus Nonoperative Management of Nonfunctioning Pancreatic Neuroendocrine Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 277-283.	1.7	48
158	Primary Hepatic Gastrinoma. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 662-663.	1.7	4
159	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 470-478.	7.0	168
160	Intraoperative radiotherapy (IORT) in the era of intensive neoadjuvant chemotherapy and chemoradiotherapy for locally advanced and borderline resectable adenocarcinoma of the pancreas (PDAC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 393-393.	1.6	1
161	Surgical management of intrahepatic cholangiocarcinoma in the modern era: advances and challenges. <i>Chinese Clinical Oncology</i> , 2016, 5, 9.	1.2	13
162	A multi-institutional phase II study of high-dose hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long-term outcomes in patients (pts) with hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 376-376.	1.6	2

#	ARTICLE	IF	CITATIONS
163	Health Insurance Expansion and Treatment of Pancreatic Cancer: Does Increased Access Lead to Improved Care?. Journal of the American College of Surgeons, 2015, 221, 1015-1022.	0.5	52
164	Melanoma initiating cells: where do we stand?. Melanoma Management, 2015, 2, 109-114.	0.5	5
165	Intracellular antigens as targets for antibody based immunotherapy of malignant diseases. Molecular Oncology, 2015, 9, 1982-1993.	4.6	22
166	FOLFIRINOX: Desert, Oasis, or Mirage?. Annals of Surgical Oncology, 2015, 22, 1059-1060.	1.5	2
167	Transcriptional control of autophagy—lysosome function drives pancreatic cancer metabolism. Nature, 2015, 524, 361-365.	27.8	624
168	Acute pancreatitis in intraductal papillary mucinous neoplasms: A common predictor of malignant intestinal subtype. Surgery, 2015, 158, 1219-1225.	1.9	42
169	Endovascular Diagnosis of Radiographically and Intraoperatively Occult Insulinoma. Journal of Vascular and Interventional Radiology, 2015, 26, 760-762.	0.5	0
170	Oncocytic-Type Intraductal Papillary Mucinous Neoplasms: A Unique Malignant Pancreatic Tumor with Good Long-Term Prognosis. Journal of the American College of Surgeons, 2015, 220, 839-844.	0.5	63
171	The Charlson age comorbidity index predicts early mortality after surgery for pancreatic cancer. Surgery, 2015, 157, 881-887.	1.9	91
172	Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer. Annals of Surgery, 2015, 261, 12-17.	4.2	717
173	Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist, 2015, 20, 1019-1027.	3.7	112
174	Multi-institutional phase II study of high dose, hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long term outcomes in patients (pts) with intrahepatic cholangiocarcinoma (ICC).. Journal of Clinical Oncology, 2015, 33, 4020-4020.	1.6	2
175	Lymphadenectomy for Pancreatic Neuroendocrine Tumors. Annals of Surgery, 2014, 259, 213-214.	4.2	9
176	Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. Radiotherapy and Oncology, 2014, 110, 160-164.	0.6	25
177	HLA Class II Antigen Expression in Colorectal Carcinoma Tumors as a Favorable Prognostic Marker. Neoplasia, 2014, 16, 31-W15.	5.3	99
178	Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. Practical Radiation Oncology, 2014, 4, e117-e123.	2.1	4
179	Understanding Hospital Readmissions After Pancreaticoduodenectomy: Can We Prevent Them?. Journal of Gastrointestinal Surgery, 2014, 18, 137-145.	1.7	88
180	Novel Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy to Eradicate Both Differentiated Cancer Cells and Cancer-Initiating Cells in Solid Tumors. Seminars in Oncology, 2014, 41, 685-699.	2.2	10

#	ARTICLE	IF	CITATIONS
181	Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: Implications of minimal involvement of the main pancreatic duct. <i>Surgery</i> , 2014, 156, 611-621.	1.9	65
182	In response to Birgir Gudjonsson, MD. <i>Surgery</i> , 2014, 156, 1286.	1.9	1
183	Single-Cell RNA Sequencing Identifies Extracellular Matrix Gene Expression by Pancreatic Circulating Tumor Cells. <i>Cell Reports</i> , 2014, 8, 1905-1918.	6.4	449
184	Mutant IDH inhibits HNF-4 α to block hepatocyte differentiation and promote biliary cancer. <i>Nature</i> , 2014, 513, 110-114.	27.8	367
185	A Phase I/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 830-838.	0.8	101
186	Effect of molecular genotyping to predict outcomes in patients with metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4128-4128.	1.6	3
187	Variability in immune infiltrates and HLA expression in cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 230-230.	1.6	2
188	Lymphoepithelial cysts and cystic lymphangiomas: Under-recognized benign cystic lesions of the pancreas. <i>World Journal of Gastrointestinal Surgery</i> , 2014, 6, 136.	1.5	6
189	Genomic profiling of intrahepatic cholangiocarcinoma: Refining prognostic determinants and identifying therapeutic targets.. <i>Journal of Clinical Oncology</i> , 2014, 32, 210-210.	1.6	2
190	Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. <i>Cancer</i> , 2013, 119, 4196-4204.	4.1	58
191	FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience. <i>Oncologist</i> , 2013, 18, 543-548.	3.7	265
192	Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2013, 257, 731-736.	4.2	344
193	Pancreatic ductal adenocarcinoma: Long-term survival does not equal cure. <i>Surgery</i> , 2012, 152, S43-S49.	1.9	182
194	Phase I/II study of preoperative (pre-op) short course chemoradiation (CRT) with proton beam therapy (PBT) and capecitabine (cape) followed by early surgery for resectable pancreatic ductal adenocarcinoma (PDAC) of the head.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4021-4021.	1.6	1
195	Twenty-Three Years of the Warshaw Operation for Distal Pancreatectomy With Preservation of the Spleen. <i>Annals of Surgery</i> , 2011, 253, 1136-1139.	4.2	123
196	Current Trends in Pancreatic Cystic Neoplasms. <i>Archives of Surgery</i> , 2009, 144, 448.	2.2	144
197	Pancreatic Fistula Rates After 462 Distal Pancreatectomies: Staplers Do Not Decrease Fistula Rates. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 1691-1698.	1.7	225